[1] Hunt CM, Papay JI, Stanulovic V, et al. Drug rechallenge following drug-induced liver injury. Hepatology, 2017, 66: 646-654.
[2] Devarbhavi H, Raj S, Arady VH, et al. Drug-induced liver injury associated with stevens-John syndrome/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases. Hepatology, 2016, 63, 993-999.
[3] Aithal G, Watkins P, Andrade R, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther, 2011, 89:806-815.
[4] Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci, 2016, 17. pii: E14. doi: 10.3390/ijms17010014.
[5] Powles T, Bracarda S, Chen M, et al. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and metaanalysis of clinical trials in advanced cancer patients. Eur J Cancer, 2015, 51:1293-1302.
[6] Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis, 2010, 50: 833-839.
[7] Hunt CM. Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. Hepatology, 2010, 52:2216-2222.
[8] Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev, 2012, 44:116-126.
[9] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med, 2015, 373: 23-34.
[10] Senior JR. Can rechallenge be done safely after mild or moderate drug-induced liver injury Hepatology, 2016, 63:691-693.
[11] Xu CF, Johnson T, Wang X, et al. HLA-B* 57: 01 Confers susceptibility to pazopanib associated liver injury in patients with cancer. Clin Cancer Res, 2016, 22:1371-1377.
[12] Reuben A, Tillman H, Fontana RJ, et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann Intern Med, 2016, 164:724-732. |
